KRAS and non-small cell lung carcinoma: The CodeBreaK 200 (NCT04303780), a randomized, controlled Phase III trial, compared AMG 510’s efficacy and safety to docetaxel in previously treated patients with advanced KRAS G12C-mutated NSCLC.